Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 801 to 810 of 1331 total matches.

Iloperidone (Fanapt) - Another Second-Generation Antipsychotic

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2010  (Issue 1332)
days Half-life 18-37 hours Metabolism CYP2D6 and CYP3A4; 2 active metabolites Table 1 ...
The FDA has approved the marketing of iloperidone (Fanapt – Vanda), a second-generation antipsychotic, for treatment of schizophrenia. Iloperidone is chemically related to risperidone (Risperdal, and others).
Med Lett Drugs Ther. 2010 Feb 22;52(1332):13-4 |  Show IntroductionHide Introduction

Two Drugs for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Sep 03, 2012  (Issue 1398)
pressure, and cause nervousness and insomnia. LORCASERIN (Belviq) — Activation of the serotonin 2C ...
In 2013 the FDA approved one new drug and a new combination of 2 old drugs as adjuncts to lifestyle changes for chronic weight management. Lorcaserin (lor-ca-SER-in; Belviq – Arena/Esai) is a selective serotonin 2C receptor agonist. Qsymia (Vivus) is a fixed-dose combination of the weight-loss drug phentermine and an extended-release (ER) formulation of topiramate. The new products are approved for use in obese patients (body mass index [BMI] of ≥30 kg/m2) and for patients who are overweight (BMI ≥27 kg/m2) and have one weight-related risk factor such as hypertension, dyslipidemia or...
Med Lett Drugs Ther. 2012 Sep 3;54(1398):69-71 |  Show IntroductionHide Introduction

Concentrated Insulin Glargine (Toujeo) for Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 11, 2015  (Issue 1468)
than Lantus, resulting in more even activity throughout the dosing period and a longer duration ...
The FDA has approved Toujeo (Sanofi), a more concentrated form of insulin glargine containing 300 IU/mL compared to the 100 IU/mL in Lantus (Sanofi). Lantus is nearing the end of its patent protection in the US, and biosimilars are expected to become available.
Med Lett Drugs Ther. 2015 May 11;57(1468):69-70 |  Show IntroductionHide Introduction

Byvalson - A Beta Blocker/ARB Combination for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Sep 12, 2016  (Issue 1503)
activity. Beta3 activation induces vasodilation through endothelial release of nitric oxide. Valsartan ...
The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan (Diovan, and generics), for treatment of hypertension. It is the only combination product that contains nebivolol, and the first to combine a beta blocker with an ARB.
Med Lett Drugs Ther. 2016 Sep 12;58(1503):115-7 |  Show IntroductionHide Introduction

Expanded Table: Some Drugs for Smoking Cessation (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019  (Issue 1576)
, or bulimia should not take bupropion ▶ Primarily metabolized by CYP2B6 to hydroxybupropion, its most active ...
View the Expanded Table: Some Drugs for Smoking Cessation
Med Lett Drugs Ther. 2019 Jul 15;61(1576):e112-4 |  Show IntroductionHide Introduction

Bempedoic Acid (Nexletol) for Lowering LDL-Cholesterol

   
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020  (Issue 1595)
OF ACTION — Bempedoic acid is activated to bempedoic acid-CoA by very-long-chain acyl-CoA synthetase 1 ...
The FDA has approved the oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid for use alone (Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption inhibitor ezetimibe (Nexlizet) as an adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-cholesterol (LDL-C). Bempedoic acid is the first ACL inhibitor to be approved in the US.
Med Lett Drugs Ther. 2020 Apr 6;62(1595):53-5 |  Show IntroductionHide Introduction

Rezafungin (Rezzayo) for Invasive Candida Infections

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
as inactive metabolites) Half-life (terminal) 152 hours ANTIFUNGAL ACTIVITY ― Rezafungin, a derivative ...
The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for once-weekly treatment of candidemia and invasive candidiasis (IC) in adults with limited or no alternative options. It is the first new drug to become available in the US in more than 15 years for treatment of systemic Candida infections.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):101-4   doi:10.58347/tml.2024.1705d |  Show IntroductionHide Introduction

Cannabis and Cannabinoids

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
Cannabis and Cannabinoids Cannabis (marijuana) contains more than 60 pharmacologically active ...
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-82 |  Show IntroductionHide Introduction

Drugs for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024  (Issue 1706)
. BISPHOSPHONATES — These nonhormonal drugs decrease bone resorption by binding to active sites of bone remodeling ...
Pharmacologic treatment is recommended for postmenopausal women who have bone density T-scores (standard deviations from normal mean values in the spine, femoral neck, total hip, or distal radius) of -2.5 or below, T-scores between -1.0 and -2.5 with a history of fragility (low-trauma) fracture of the hip or spine, or T-scores between -1.0 and -2.5 with a FRAX 10-year probability of ≥3% for hip fracture or ≥20% for major osteoporotic fracture.
Med Lett Drugs Ther. 2024 Jul 8;66(1706):105-12   doi:10.58347/tml.2024.1706a |  Show IntroductionHide Introduction

Methylphenidate Revisited

   
The Medical Letter on Drugs and Therapeutics • May 06, 1988  (Issue 765)
of motor activity, impulsivity, and inattention; boys are affected more often than girls (R McGee et al, J ...
Methylphenidate (Ritalin and others), a Schedule II controlled substance in the USA, is a short-acting central-nervous-system stimulant widely used for treatment of children with school performance or behavior problems, or what is now called Attention Deficit-Hyperactivity Disorder, or AD-HD (American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, third ed., revised [DSM-III R], Washington, DC:authors, 1987, p 50). Some studies have estimated that more than 3% of elementary school students are taking methylphenidate, and one parents' group has brought a...
Med Lett Drugs Ther. 1988 May 6;30(765):51-2 |  Show IntroductionHide Introduction